For physician entrepreneurs and strategic acquirers, acquiring an established dermatology clinic with a proven patient base and payer contracts almost always outperforms the time, cost, and risk of building from zero — but the right answer depends on your capital position, clinical team, and growth strategy.
Dermatology is one of the most sought-after specialties in lower middle market healthcare M&A. With a $20 billion U.S. market, high-margin cosmetic revenue, recession-resistant demand, and a highly fragmented independent practice landscape, dermatology sits at the intersection of everything acquirers want. But for buyers entering the space — whether a physician entrepreneur using SBA financing or a PE-backed roll-up platform — the foundational question remains: is it smarter to acquire an existing practice at a 4–7x EBITDA multiple, or to build a de novo clinic from the ground up? This analysis breaks down both paths across cost, timeline, risk, and strategic fit to help you make a data-driven decision.
Find Dermatology Practice Businesses to AcquireAcquiring an established dermatology practice gives you immediate access to an existing patient base, contracted payer relationships, licensed clinical staff, and a functioning revenue cycle. For buyers who value speed to cash flow and want to minimize the execution risk of standing up clinical operations, acquisition is almost always the more efficient capital deployment — particularly when seller financing or SBA 7(a) loans can fund 80–90% of the purchase price.
PE-backed dermatology roll-up platforms adding geographic density, physician entrepreneurs with access to SBA 7(a) financing seeking an established practice with a clinical team, and medical groups looking to enter a new market without the 2–3 year ramp of a de novo launch.
Building a dermatology practice from scratch offers complete control over clinical model, branding, technology stack, and culture — and eliminates the premium paid on acquired goodwill. However, de novo dermatology clinics face a punishing ramp period driven by physician credentialing timelines, payer contracting delays, equipment capital requirements, and the slow accumulation of a patient base in a specialty where referral relationships and reputation are everything.
Experienced dermatologists with an existing patient following who are leaving a group practice and bringing their panel with them, or well-capitalized health systems entering a new market with an already-recruited clinical team and guaranteed referral volume.
For the overwhelming majority of buyers in the lower middle market — including physician entrepreneurs, PE-backed roll-up platforms, and medical groups — acquiring an established dermatology practice is the superior path. The combination of immediate cash flow, inherited payer contracts, an existing clinical team, and a proven cosmetic revenue stream far outweighs the acquisition premium when financed efficiently through SBA 7(a) lending or PE capital. De novo builds make sense only in narrow scenarios where a dermatologist is relocating their own patient panel or a well-capitalized system can absorb a 2–3 year cash burn with pre-committed referral volume. For everyone else, the question is not whether to buy — it is how to find, evaluate, and structure the right deal.
Do you already have a board-certified dermatologist committed to the venture, or will you need to recruit one — because without a physician in place, a de novo build is nearly impossible to execute in this specialty?
Can you absorb 18–36 months of negative or breakeven cash flow while a de novo practice ramps, or do you need immediate revenue to service acquisition debt and generate investor returns?
Is there an acquisition target available in your target market at a reasonable valuation, or is the local market either overpriced or without viable sellers — making a build the only practical entry option?
What is your strategic goal — do you want to build a single scalable practice with full control over culture and infrastructure, or do you want to deploy capital quickly and add clinical capacity to an existing platform?
How do corporate practice of medicine laws in your target state affect ownership structure — and do you have the legal and operational infrastructure to execute an MSO-based acquisition versus the simpler startup structure of a physician-owned de novo?
Browse Dermatology Practice Businesses For Sale
Skip the build phase — acquire existing customers, revenue, and cash flow from day one.
Dermatology practices in the lower middle market typically trade at 4–7x EBITDA. Practices with strong cosmetic revenue, multiple licensed providers, diversified payer mix, and minimal key-person dependency command the higher end of that range. Solo-physician practices with heavy Medicare concentration and no cosmetic component typically trade closer to 4–5x. PE-backed platforms often pay above-market multiples — sometimes 7–10x — for practices that fit tightly into a roll-up thesis with geographic density.
Yes — dermatology practice acquisitions are SBA 7(a) eligible, and this is one of the most common financing structures for physician entrepreneur buyers in the lower middle market. A typical deal is structured with an SBA 7(a) loan covering 75–85% of the purchase price, a seller note of 10–15%, and buyer equity injection of 10–15%. The SBA requires the acquiring entity to be operationally active, and in states with corporate practice of medicine restrictions, the loan must be structured through an MSO or similar compliant entity. Loan sizing generally supports acquisitions up to $5M.
Corporate practice of medicine (CPOM) laws in many states — including California, New York, and Texas — prohibit non-physician entities from owning or controlling a medical practice. This is a critical deal structuring issue in dermatology acquisitions. The most common solution is a Management Services Organization (MSO) structure, where a non-physician buyer owns and operates the management company (handling billing, HR, facilities, and administration) while a physician-owned Professional Corporation (PC) retains the clinical entity and licenses. Any buyer acquiring a dermatology practice must engage a healthcare M&A attorney with CPOM expertise in the target state before structuring the deal.
Key-person dependency is the single largest risk in most dermatology acquisitions. When one physician drives 70–80% or more of patient volume, collections, and cosmetic revenue, the departure of that physician post-close can devastate practice value almost overnight. Buyers must negotiate meaningful retention packages, physician equity rollover, and enforceable non-compete agreements as a condition of any acquisition. Secondary risks include inherited malpractice exposure, undisclosed payer contract renegotiations, and EMR migration disruptions that can disrupt billing during transition.
Building a de novo dermatology practice takes 24–36 months to reach stabilized operations comparable to an established acquired practice. The timeline is largely driven by payer credentialing (6–18 months), patient base accumulation, and equipment procurement. By contrast, an acquisition delivers immediate revenue on day one of closing, with operational normalization typically within 90–180 days. For most buyers, the 2–3 year ramp of a de novo build — combined with $800K–$2.5M in startup capital and the complexity of recruiting a dermatologist into a new practice — makes acquisition the dramatically more efficient path to a functioning, cash-flowing business.
More Dermatology Practice Guides
Get access to acquisition targets with real revenue, real customers, and real cash flow.
Create your free accountNo credit card required
For Buyers
For Sellers